Community
Company
News
Contact Us
Sign in

Please select the option that best describes you:

Topics: Rheumatology • Osteoporosis

Are there any concerns with using denosumab in a patient with chronic hepatitis B infection on antiviral therapy?

Related Questions

Would you use PTH analog in a patient with severe osteoporosis (T score below - 3.5) who has been found to have idiopathic hypercalciuria with normal labs (PTH, vit D, Ca)?

For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?

Are there any concerns with live vaccine innoculation and patients who are on denosumab?

How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?

During treatment of severe osteoporosis, with PTH analogs (abaloparatide or) would rise in alkaline phosphatase level > 200 (in setting of normal GGT) warrant discontinuation of medication?

Do you routinely use anti-resorptive medications in patients who have osteoporosis and longstanding hypoparathyroidism?

What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?

Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?

How would you manage a middle-aged patient with Paget's disease who received one dose of zolendronic acid 2 years ago, currently suppressed CTX, normal bone-specific Alkaline phos, and a recent hairline fracture in the thoracic spine?

How do you use P1NP in your clinical practice to guide management of osteoporosis?

Copyright © 2025 theMednet
All Rights Reserved.